PADI4 polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis
Modern Rheumatology, 05/07/2012
Evidence Based Medicine
Hou S et al. – This meta–analysis suggests that peptidylarginine deiminase 4 (PADI4) polymorphisms represent a significant risk factor for rheumatoid arthritis (RA), especially in Asians.Methods
- An electronic searching strategy was employed to collect relevant studies on the association between PADI4 polymorphism and susceptibility to RA.
- The odds ratio (OR) with the 95 % confidence interval (95 % CI) was used to evaluate the RA risk presented by PADI4 polymorphism.
- Fixed or random effects models were selected based on heterogeneity.
- Publication bias was assessed using funnel plots, Begg’s test, and Egger’s test. A total of 27 studies from 21 articles were included.
- Six gene loci (padi4_94, 104, 92, 90, 89, and 100) were chosen for the meta–analysis.
- The pooled ORs (95 % CI) for allele 2 versus 1 were 1.08 (1.05–1.12), 1.17 (1.12–1.23), 1.26 (1.18–1.36), 1.17 (1.10–1.24), 1.30 (1.17–1.44), and 1.25 (1.11–1.40), respectively.
- All six SNPs were significantly associated with RA in Asian populations.
- Three SNPs (PADI4_104, 90, 89) showed significant associations, while the other three SNPs (PADI4_94, 92, 100) exhibited no associations in the European population.
- A dose–response relationship between allele 2 of PADI4 and the risk of RA was also identified.